A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis

Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/3614
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/3646
dc.contributor.author Menzin, Joseph
dc.contributor.author Oster, Gerry
dc.contributor.author Davies, Linda
dc.contributor.author Drummond, Michael F.
dc.contributor.author Greiner, Wolfgang
dc.contributor.author Lucioni, Carlo
dc.contributor.author Merot, Jean-Luis
dc.contributor.author Rossi, Franco
dc.contributor.author Schulenburg, Johann-Matthias Graf von der
dc.contributor.author Souêtre, Eric
dc.date.accessioned 2018-08-23T12:15:43Z
dc.date.available 2018-08-23T12:15:43Z
dc.date.issued 1996
dc.identifier.citation Menzin, J.; Oster, G.; Davies, L.; Drummond, M.F.; Greiner, W. et al.: A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. In: International Journal of Technology Assessment in Health Care 12 (1996), Nr. 1, S. 52-61. DOI: https://doi.org/10.1017/S0266462300009387
dc.description.abstract Economic evaluations of pharmaceuticals are increasingly being conducted in conjunction with randomized phase III clinical trials to meet the demand for pharmacoeconomic data when new products are launched. While the need for such data is often global, the trials in which relevant information may be collected are often conducted in only one or a limited number of countries. A critical issue is how data from pivotal clinical trials in one setting can serve as the basis for pharmacoeconomic evaluations in others. We address this issue and report on four economic evaluations that we undertook in conjunction with a recent U.S. phase III clinical trial of recombinant human deoxyribonuclease (rhDNase), which is used to improve pulmonary function in patients with cystic fibrosis (CF). The objective of these evaluations was to estimate the potential impact of rhDNase therapy in France, Germany, Italy, and the United Kingdom on the direct costs of medical care for the treatment of respiratory tract infections (RTIs) in patients with C. Analyses of economic impact were undertaken both with and without adjustment for differences in practice patterns between the United States and the countries of interest. Our findings suggest that rhDNase therapy may reduce the cost of RTI-related care by between US$600 and US$1,100 over a 24-week period; the cost of rhDNase is not included in these figures, as a price was unavailable when our analyses were undertaken. Despite methodologic challenges, economic evaluations that meet the information needs of decision makers in diverse countries can nonetheless be undertaken in conjunction with phase III clinical trials. eng
dc.language.iso eng
dc.publisher Cambridge : Cambridge University Press
dc.relation.ispartofseries International Journal of Technology Assessment in Health Care 12 (1996), Nr. 1
dc.rights Es gilt deutsches Urheberrecht. Das Dokument darf zum eigenen Gebrauch kostenfrei genutzt, aber nicht im Internet bereitgestellt oder an Außenstehende weitergegeben werden. Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
dc.subject antibiotic agent eng
dc.subject dornase alfa eng
dc.subject placebo eng
dc.subject adult eng
dc.subject aerosol eng
dc.subject antibiotic therapy eng
dc.subject child eng
dc.subject clinical trial eng
dc.subject controlled clinical trial eng
dc.subject controlled study eng
dc.subject cost control eng
dc.subject cystic fibrosis eng
dc.subject female eng
dc.subject forced expiratory volume eng
dc.subject health care cost eng
dc.subject health care utilization eng
dc.subject health economics eng
dc.subject hospital admission eng
dc.subject human eng
dc.subject incidence eng
dc.subject intravenous drug administration eng
dc.subject lung function eng
dc.subject major clinical study eng
dc.subject male eng
dc.subject nebulizer eng
dc.subject oral drug administration eng
dc.subject phase 3 clinical trial eng
dc.subject randomized controlled trial eng
dc.subject respiratory tract infection eng
dc.subject review eng
dc.subject Clinical Trials, Phase III eng
dc.subject Cystic Fibrosis eng
dc.subject Deoxyribonuclease I eng
dc.subject Drug Costs eng
dc.subject Europe eng
dc.subject Expectorants eng
dc.subject Health Care Costs eng
dc.subject Humans eng
dc.subject International Cooperation eng
dc.subject Physician's Practice Patterns eng
dc.subject Recombinant Proteins eng
dc.subject Statistics, Nonparametric eng
dc.subject United States eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.subject.ddc 330 | Wirtschaft ger
dc.title A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis
dc.type review
dc.type Text
dc.relation.issn 02664623
dc.relation.doi https://doi.org/10.1017/S0266462300009387
dc.bibliographicCitation.issue 1
dc.bibliographicCitation.volume 12
dc.bibliographicCitation.firstPage 52
dc.bibliographicCitation.lastPage 61
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Files in this item

This item appears in the following Collection(s):

Show simple item record

 

Search the repository


Browse

My Account

Usage Statistics